SEARCH

SEARCH BY CITATION

The images for figures 3, 4, and 5 were incorrect in the published versions of the article. The correct images and figures follow. The publisher regrets the error.

Figure 3, page 886:

thumbnail image

Figure 3. Plantarflexor fatigability in sedentary, novel exercise, and accustomed exercise groups after 28 days of normal cage activity (Sedentary), 14 days of normal cage activity and 14 days of running wheel access (Novel), or 28 days of running wheel access (Accustomed), with saline or cerivastatin (1 mg/kg) during the final 14 days of treatment. Fatigue was calculated as percent maximal isometric force on the tenth repetition. A significant activity × treatment interaction was found for fatigability, with both sed/statin and novel/statin groups showing reduced isometric force on the tenth contraction compared with their respective saline-treated groups. Data expressed as mean + SE. *P < 0.05 vs. corresponding saline group.

Download figure to PowerPoint

Figure 4, page 887:

thumbnail image

Figure 4. Average changes in Hsp25 (A) and αB-crystallin (aBC) (B) protein in gastronemius muscles in sedentary, novel exercise, and accustomed exercise groups after 28 days of normal cage activity (sedentary), 14 days of normal cage activity and 14 days running wheel access (Novel), or 28 days of running wheel access (Accustomed), with saline or cerivastatin (1mg/kg) during the final 14 days of treatment. Representative Western blots for Hsp25 and αB-crystallin for all groups are shown. A significant main effect for activity was found for both Hsps, with significant increases in both novel and accustomed exercise groups. Statin treatment did not significantly affect Hsp expression under any activity condition. Data expressed as mean + SE. *P < 0.05 vs. non-exercise controls.

Download figure to PowerPoint

Figure 5, page 887:

thumbnail image

Figure 5. Average changes in activated caspase-9 protein levels in gastronemius muscles in sedentary, novel exercise, and accustomed exercise groups after 28 days of normal cage activity (sedentary), 14 days of normal cage activity and 14 days of running wheel access (Novel), or 28 days of running wheel access (Accustomed), with saline or cerivastatin (1 mg/kg) during the final 14 days of treatment. Representative Western blots for activated caspase-9 and -3 for all groups are shown. Active caspase-3 was not detectable in any group. Positive control shows Jurkat cells treated with cytochrome-c to activate caspase-3. A significant activity × treatment interaction was found, with statin treatment increasing caspase-9 expression in sedentary and novel exercise groups, but decreasing expression in accustomed exercise groups. No significant individual group differences were found. Data expressed as mean + SE.

Download figure to PowerPoint